For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
A Fiery First Republican Debate — Without Trump
Ready or Not, Driverless Cars Are Here
Why the Coral Reef Crisis in Florida Is a Problem for All of Us
Inside the Sputtering Campaign of Ron DeSantis
The Sunday Read: ‘The Ongoing Mystery of Covid’s Origin’
How a Paradise Became a Death Trap
Hunter Biden’s Legal Problems Keep Getting Worse
Why a Coup in Niger Has the World’s Attention
A Law Used Against the Mafia — and Now Trump
What Lahaina Lost in Hawaii’s Wildfires
The Sunday Read: ‘The Silicon Blockade’
The End of An Era for U.S. Women’s Soccer
Lives, Livelihoods, and the High Cost of Heat
Elon Musk’s Quest to Own the Stars
The Legal Strategy Behind the Latest Trump Indictment
The Economy is on an Upswing. Should Biden Get Credit for It?
The Sunday Read: ‘The Vanishing Family: Life in the Shadow of a Cruel Genetic Mutation’
Fighting Canada’s Unending Fires
43% vs. 43%: Why Trump and Biden Are Tied in Our New Poll
The Charges Against Trump for Conspiring to Overturn the Election
Create your
podcast in
minutes
It is Free
Up First
Post Reports
What Next | Daily News and Analysis
Consider This from NPR
The World